Search

Discusses results of a study on the long-term effects of raloxifene hydrochloride on bone mineral density, bone loss and serum lipid levels in early postmenopausal women in the United States. Percent reduction of serum low-density lipoprotein cholesterol; Adverse effects.

Presents a letter to the editor in response to a study of endometrial cancer and hormone-replacement therapy, published in the April 30, 2005 edition of "The Lancet."

A letter to the editor is presented in response to an article on drug treatments for obesity by Raj Padwal and Sujit Majurndar published in the January 6, 2007 issue.

A letter to the editor is presented in response to the article "Ten Years of Alendronate Treatment for Osteoporosis in Postmenopausal Women," from the March 18, 2004 issue.